Windtree Therapeutics has confirmed its suspension from Nasdaq effective August 21, as it could not uphold the minimum requirement of 1.00 USD per share. This decision comes after a controversial plan to buy 700 million USD in Binance’s BNB token did not raise its stock price.
Since its listing in May 2020, Windtree has repeatedly encountered compliance issues with Nasdaq, facing multiple warnings due to bid-price violations. Experts indicate that companies transitioning to digital assets often struggle with credibility, impacting their market performance.
Leave a Reply